Search clinical trials for: MK0767

Total 159 results

Merck Sharp & Dohme LLC

Terminated

MK0767 and Sulfonylurea Combination Study (0767-027)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Dyslipidemia in Type 2 Diabetes (0767-034)

Dyslipidemia | Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Terminated

MK0767 in Type 2 Diabetes (0767-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Study A - MK0767 Monotherapy Study

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Anxiety Disorders
Merck Sharp & Dohme LLC

Terminated

Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Hip Fracture

Germany, Norway, Spain, Sweden, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

MK0767 and Metformin Combination Study (0767-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Anxiety Disorder (0777-022)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Merck Sharp & Dohme LLC

Completed

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Terminated

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)

Pain, Postoperative
Merck Sharp & Dohme LLC

Completed

MK0457 in Patients With Leukemia (0457-003)

Myelodysplastic Syndromes | Myelogenous Leukemia, Chronic | Chronic Myelogenous Leukemia in Blast Crisis | Lymphocytic Leukemia, B Cell, Acute
Merck Sharp & Dohme LLC

Terminated

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Terminated

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Leukemia
Merck Sharp & Dohme LLC

Completed

A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)

Cancer
Merck Sharp & Dohme LLC

Terminated

Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Advanced Breast Cancer | Other Solid Tumors
Merck Sharp & Dohme LLC

Completed

Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)

Hypertension
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Merck Sharp & Dohme LLC

Terminated

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute, T-cell | Myelogenous Leukemia
Merck Sharp & Dohme LLC

Terminated

The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

Middle Cerebral Artery Stroke
Merck Sharp & Dohme LLC

Completed

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Schizophrenia | Paranoid Schizophrenia
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

Advanced Solid Tumors

Canada, United States
Merck Sharp & Dohme LLC

Terminated

MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)

Metabolic X Syndrome Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Colorectal Cancer | Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Anxiety Disorder
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Sarcoma | Lymphoma | Kidney Cancer | Testicular Germ Cell Tumor | Breast Cancer | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma

United States
Merck Sharp & Dohme LLC

Completed

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Obesity
Organon and Co

Completed

A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)

Osteoporosis
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

Diabetes Type 2

United States, Canada, Korea, Republic of, Australia
Organon and Co

Completed

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

Migraine Headache
Merck Sharp & Dohme LLC

Terminated

12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)

Arthritis, Rheumatoid | Osteoarthritis
Merck Sharp & Dohme LLC

Completed

MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)

Duodenal Ulcer | Stomach Ulcer
Organon and Co

Completed

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Paget's Disease of Bone
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada, Spain
Organon and Co

Completed

An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)

Dysmenorrhea
Organon and Co

Completed

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

Acute Pain Following a Total Abdominal Hysterectomy
Merck Sharp & Dohme LLC

Terminated

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Chronic Myelogenous Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Organon and Co

Completed

Treatment of Multiple Attacks of Acute Migraine (0462-025)

Migraine Headache
Cardinal Tien Hospital

Completed

Evaluation of the Effects of Simvastatin 40mg

Hypercholesterolemia
Organon and Co

Completed

Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)

Hypercholesterolemia

3

Subscribe